REG - Intuitive Invests.Gp - Proposed Investment in Kromek Pharma plc

Intuitive InvestmentsAnnouncement

12/02/2021 11:45

RNS Number : 9734O
  
Intuitive Investments Group plc
  
12 February 2021
  
 

12 February 2021 
Intuitive Investments Group plc
Proposed Investment in Kromek Pharma plc
Intuitive Investments Group plc (AIM: IIG) ("IIG"), a closed-end investment company focussed on the life sciences sector, announces an investment of £249,975 to acquire 1.66 million ordinary shares of Kromek Group plc (AIM:KMK) ("Kromek") at a price of 15 pence per share (the "Investment"). The Investment is part of the fundraising announced by Kromek on 12 February 2021. The Investment is conditional upon, amongst other things, the resolutions being passed at Kromek's forthcoming general meeting on 1 March 2021.
Kromek Group plc is a worldwide supplier of detection technology focusing on the medical, security screening and nuclear markets. 
The Investment in Kromek is the Company's fifth investment following its IPO in mid-December 2020.
For further information, please contact:



Intuitive Investments Group plc


 




David Evans


Via Walbrook PR




 


 




Strand Hanson Limited - Nominated Adviser


+44 (0) 20 7409 3494




James Harris / James Dance / James Bellman
 


















Turner Pope Investments (TPI) Ltd - Broker


+44 (0) 20 3657 0050




Andrew Thacker / Zoe Alexander


 




 


 




Walbrook PR Limited - Media & Investor Relations


+44 (0)20 7933 8780 or intuitive@walbrookpr.com




Paul McManus


+44 (0) 7980 541 893



 
About Intuitive Investments Group plc
 The Company is a newly established investing company, seeking to provide investors with exposure to a portfolio concentrating on fast growing and/or high potential Life Sciences businesses operating predominantly in the UK, continental Europe and the US, utilising the Board's experience and in particular that of the Chairman, David Evans, to seek to generate capital growth over the long term for shareholders.
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
MSCTTMBTMTJBBPB